Ferrous Bisglycinate as a well-tolerated API against Iron Deficiency Anemia
Dr. Paul Lohmann® is the world's first manufacturer of Ferrous Bisglycinate as an active pharmaceutical ingredient (API), which is available including the API documentation (DMF/ASMF) for the registration of a drug with the health authorities.
Ferrous Bisglycinate is a fully reacted Iron Salt based on glycine with a low heavy metal content and an improved solubility and dissolution profile.1 The glycine chelate structure protects the highly reactive Iron from redox reactions in the gastrointestinal tract and thus prevents unpleasant side effects such as epigastric pain, nausea, vomiting and abdominal cramps.2 Due to its high bioavailability and tolerance during use, Ferrous Bisglycinate is ideally suited as an API for the treatment of Iron deficiency anemia and for the prevention of Iron status disorders in pregnant women and breastfeeding mothers.3
References:
1 Name, J. J., et al. Iron Bisglycinate Chelate and Polymaltose Iron for the Treatment of Iron Deficiency Anemia: A Pilot Randomized Trial; 2018, 14(4), 261-268.
2. Ferrari, P., et al. Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedicine & Pharmacotherapy, 2012, 66(6), 414-418.
3. Soppi, E. T. Iron deficiency without anemia – a clinical challenge, Clinical Case Reports, 2018, 6(6), 1082-1086.
Related News
-
Sponsored Content IFF Pharma Solutions: Paving the Way for Superior Suspensions
Shawn Branning, Global Strategic Marketing Manager at IFF – Pharma Solutions -
News Greenfield Global Ireland Ready to Supply Life Science Customers Globally
New facility aims to serve local and global pharmaceutical customers with high-purity ethanol, ethanol blends and buffer solutions -
News Rare diseases care pathway: a major challenge to harmonize patient management
In France, rare diseases are numerous: between 7,000 and 8,000 diseases are currently accounted for, and concern more than 3 million French people, accounting for almost 4,5% of the total population. The organization of screening and care for these ill... -
Sponsored Content CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner
Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and... -
Sponsored Content Sterile manufacturing Annex 1 amendments: what, why and how explained
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected... -
News Recipharm expands its analytical services offering in India
The CDMO inaugurates its new analytical laboratory under Recipharm Analytical Solutions -
News Tikun Olam-Cannbit and Wavelength strike novel cannabis agreement
Firms say the partnership will "multiply the power of both companies, the pharmaceutical industry and the medical cannabis industry" -
News Pharmapack interviews Serkan Oray of UCB Pharma
Ahead of Pharmapack Europe 2021 in October, we talk to one of the speakers, Serkan Oray, Vice President, Devices, Packaging & Wearable Technologies at UCB Pharma about the company's new electromechanical injection device and the innovation drive wi...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance